Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05190445 · ClinicalTrials.gov registry record · Phase 2
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
A Phase 2 study of HER2-positive Gastric Cancer, sponsored by Pieris Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 5
- Study locations
NCT05190445: Active Phase 2 study of HER2-positive Gastric Cancer, sponsored by Pieris Pharmaceuticals.
NCT05190445 is a Phase 2 study of HER2-positive Gastric Cancer that is active but no longer recruiting, run by Pieris Pharmaceuticals. The registered enrollment target is 80 participants, below the 318-participant average among 6 other HER2-positive Gastric Cancer trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05190445, a Phase 2 study of HER2-positive Gastric Cancer, is active but no longer recruiting, sponsored by Pieris Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Conditions Studied
Interventions
- DRUG Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel
- DRUG Cinrebafusp alfa (PRS-343) in combination with tucatinib
Study Locations (5)
California
- Sansum Clinic - Santa Barbara
Maryland
- Maryland Oncology-Hematology - Silver Spring
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- University of Texas MD Anderson Cancer Center - Houston
Other
- Samsung Medical Center - Seoul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2023-02-01 |
| Phase | Phase 2 |
What the registry record for NCT05190445 still lists
NCT05190445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 318-participant average among 6 other HER2-positive Gastric Cancer trials with a reported enrollment target (75% lower).
The record links to 1 condition, with HER2-positive Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel is the first listed.
NCT05190445 lists 5 locations in 5 states (California, Maryland, New York).
Frequently Asked Questions
What is clinical trial NCT05190445 about?
NCT05190445 is a clinical study titled "Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma". A Phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.
What is the current status of trial NCT05190445?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2021-11-01. Estimated completion is 2023-02-01.
What conditions does trial NCT05190445 study?
This clinical trial studies the following conditions: HER2-positive Gastric Cancer.
What interventions are being tested in trial NCT05190445?
The interventions under investigation include: Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel (DRUG), Cinrebafusp alfa (PRS-343) in combination with tucatinib (DRUG).
Who is sponsoring clinical trial NCT05190445?
This trial is sponsored by Pieris Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05190445 being conducted?
This trial has 5 study locations across California, Maryland, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
RECRUITING · Phase 3
-
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
RECRUITING · Phase 1
-
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
RECRUITING · Phase 3
-
HER-2 B Cell Peptide Vaccine
RECRUITING · Phase 1
-
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI